$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How often should you lose nivolumab
2025-10-19 11:44:20
Check Details
Conditional activation blocks VISTA to inhibit solid tumors, and the US FDA approves the new drug research application of SNS-101
2025-10-19 11:44:20
Check Details
Acting on the tumor microenvironment, Parthenon announced that the self-developed drug PRTH-101 has completed the first patient administration in the phase I clinical trial
2025-10-19 11:44:20
Check Details
Innovent Biologics/Eli Lilly's RET inhibitor "Seputinib" is officially commercialized in China_Canghule
2025-10-19 11:44:20
Check Details
Express delivery! Novartis c-Met inhibitor "capmatinib" applies for marketing in China
2025-10-19 11:44:20
Check Details
The efficacy of nivolumab in treating gastric cancer: is it an immune drug or a targeted drug?
2025-10-19 11:44:20
Check Details
What is the effect of nivolumab combined with chemotherapy? What drug should be used with chemotherapy?
2025-10-19 11:44:20
Check Details
Is gefitinib a targeted drug and is it effective?
2025-10-19 11:44:20
Check Details
What are the indications and pharmacological effects of erlotinib?
2025-10-19 11:44:20
Check Details
Is afatinib effective and how to take it?
2025-10-19 11:44:20
Check Details
Is it necessary to take afatinib for early stage lung cancer? What are the adverse reactions?
2025-10-19 11:44:20
Check Details
Afatinib is a targeted drug of several generations. What diseases does it mainly treat?
2025-10-19 11:44:20
Check Details
1
2
...
4120
4121
4122
4123
4124
4125
4126
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
2
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
3
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
4
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
5
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
6
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
7
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
8
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
9
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
10
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
11
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor
12
Alpelisib: From Breast Cancer to PIK3CA-Related Overgrowth Spectrum